Physician profile
Kerri Smith
NPI 1316306194
$2,635.68
in general payments reported to CMS, 2019-2025
37 companies · $80.92 in 2025
The $80.92 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,338 · 2022: $474 · 2024: $743 · 2025: $80.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794 · Travel and Lodging: $30.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $793.96 |
| Travel and Lodging | $30.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,023.10 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.37 | 2021-2022 | |
| Gilead Sciences, INC. | $129.67 | 2021-2022 | |
| Galderma Laboratories, L.P. | $123.64 | 2024 | |
| Sunovion Pharmaceuticals INC. | $88.62 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.15 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $85.40 | 2022 | |
| Revance Therapeutics, INC. | $77.52 | 2024-2025 | Daxxify |
| Merck Sharp & Dohme LLC | $73.71 | 2021 | |
| Dexcom, INC. | $60.51 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $56.31 | 2021 | |
| Braintree Laboratories, INC. | $53.79 | 2021 | |
| Ucb, INC. | $48.96 | 2021 | |
| Sk Life Science, INC. | $41.33 | 2021-2022 | |
| Amarin Pharma, INC. | $39.96 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $39.80 | 2021-2022 | |
| Biogen, INC. | $36.05 | 2022 | |
| Medtronic, INC. | $32.37 | 2021 | |
| Ge Healthcare | $32.10 | 2021-2022 | |
| Lundbeck LLC | $31.57 | 2021 | |
| Neurocrine Biosciences, INC. | $30.81 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.66 | 2021 | |
| Vanda Pharmaceuticals INC. | $28.55 | 2021 | |
| Janssen Biotech, INC. | $28.46 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $21.02 | 2022 | |
| Supernus Pharmaceuticals, INC. | $19.77 | 2022 | |
| Genzyme Corporation | $18.72 | 2021 | |
| Celgene Corporation | $16.45 | 2022 | |
| Ascensia Diabetes Care US INC. | $15.48 | 2021 | |
| Amryt Pharma Holdings LTD | $15.03 | 2021 | |
| Ibsa Pharma INC. | $14.81 | 2021 | |
| Corcept Therapeutics | $14.65 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.18 | 2021 | |
| Akcea Therapeutics, INC. | $13.78 | 2021 | |
| Ferring Pharmaceuticals INC. | $13.05 | 2022 | |
| Upsher-Smith Laboratories LLC | $11.87 | 2021 | |
| Antares Pharma, INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerri Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.